Shares of Haleon plc (LON:HLN – Get Free Report) have earned a consensus rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is GBX 399.
HLN has been the topic of several recent analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research report on Thursday, June 25th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 400 price target on shares of Haleon in a research note on Friday, July 31st. Berenberg Bank raised their price target on Haleon from GBX 512 to GBX 514 and gave the company a “buy” rating in a report on Wednesday, August 5th. Royal Bank Of Canada increased their target price on Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a research report on Tuesday, August 11th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on Haleon from GBX 325 to GBX 335 and gave the company a “sell” rating in a research note on Friday, July 31st.
Get Our Latest Analysis on Haleon
Haleon Price Performance
Haleon (LON:HLN – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported GBX 8.60 earnings per share for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. As a group, research analysts anticipate that Haleon will post 19.5033282 earnings per share for the current year.
Haleon Company Profile
Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.
Recommended Stories
- Five stocks we like better than Haleon
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
